Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Detalles Bibliográficos
Autores principales: Cervantes, Francisco, Ross, David M., Radinoff, Atanas, Palandri, Francesca, Myasnikov, Alexandr, Vannucchi, Alessandro M., Zachee, Pierre, Gisslinger, Heinz, Komatsu, Norio, Foltz, Lynda, Mannelli, Francesco, Passamonti, Francesco, Gilotti, Geralyn, Sadek, Islam, Tiwari, Ranjan, Zor, Evren, Al-Ali, Haifa Kathrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119245/
https://www.ncbi.nlm.nih.gov/pubmed/34475521
http://dx.doi.org/10.1038/s41375-021-01396-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119245/
https://www.ncbi.nlm.nih.gov/pubmed/34475521
http://dx.doi.org/10.1038/s41375-021-01396-x

Ejemplares similares